




PHARMACEUTICAL 2020

Skye Bioscience Inc.
Rank 139 of 358





PHARMACEUTICAL 2020

Skye Bioscience Inc.
Rank 139 of 358

The relative strengths and weaknesses of Skye Bioscience Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Skye Bioscience Inc. compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 447% points. The greatest weakness of Skye Bioscience Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 146% points.

The company's Economic Capital Ratio, given in the ranking table, is 116%, being 79% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	1,995
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	971
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	1.6
Other Liabilities	478
Other Net Income	7,686
Other Revenues	0
Property and Equipment	2.0
Research and Development	2,238
Selling, General and Administrative Expense	4,395

Output Variable	Value in 1000 USD
Assets	1,997
Liabilities	1,449
Expenses	6,634
Revenues	0
Stockholders Equity	548
Net Income	1,052
Comprehensive Net Income	1,052
Economic Capital Ratio	116%